Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. The company's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), received the “Notice of Acceptance” from the State Drug Administration, and Jinsai Pharmaceutical's application for registration of domestically produced drugs for fuxinqibizumab injection was accepted. Fuchinzibimab is a wholly human anti-interleukin-1beta (IL-1beta) monoclonal antibody developed by Jinsai Pharmaceutical. It is intended to treat connective tissue disease-related interstitial lung disease (CTD-ILD).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.